WindMIL Therapeutics and Universit★÷y of California, Irvi♠☆₩ne Announce Collaboration to Collect Bo βne Marrow from Patients with G♦≈✔liomasWEDNESDAY, OCTOBER 16, 2019Wi<​ndMIL Therapeutics and the Universiφ≤™↑ty of California, Irvine (UCI) today © announced that the first patient¥↑∏≤s have been identifiδ€₽€ed in an investigator-sponsored study fo≈₹>σr the collection of bone marrow from"¥ patients with gliomas. The study will∑☆ evaluate generating marrow infiltrati≠‌¥ng lymphocytes (MILs™) for th✔εσese patients through₩♥Ωλ WindMIL’s proprietary cellular Ω•‌♦activation and expan∏δ≥♦sion process. The study ‍§is being conducted at ✘≠ UCI.“Patients suffering with glio©λπ'blastoma are in great need of new, promi$₽∑sing treatments that might ♠☆advance the current standard o→↑≈f care,” said Daniela A. Bota, MD, PhD, di∏λ∞βrector of the UCI Health Comprehensive BΩ↓δrain Tumor Program, se∑♣αnior associate dean for clinical research,≈★€ UCI School of Medicine and cli¥♥nical director, UCI Sue & Bill Gross S§¥λ↕tem Cell Research Cen♥≈ter. “The University of California, Irvin‌ ©e is excited to play a key role≤↓ in research that may lead to a clinicaΩα♥l trial that enlists the i♦™γmmune system in novel way× σs to fight this terrible disease.”Gliomas a∞ "♥re the most common of the malignant brain₩" $ tumors. Glioblastoma, the most c₽≤ommon glioma, has a five-←↔≠★year survival of less tha™ n 5 percent. Additional treatment option≥π™‍s are urgently needed fo±​φr these patients. Adoptive immunotherapy is a po↕♣↔ssible approach for gliomas and tγ★™he use of MILs, a cell therapy that is natur ♥≤Ωally tumor-specific, is one such trea✔→£tment option.The bone ‌π‌←marrow is a unique niche in the immune system to•♦γ§ which antigen-experienced memory T cell₹☆s traffic and are then maintained. WindMI÷∑± L has developed a prop $σ←rietary process to select, activ™∞↓ate and expand these memory T cell←₹¶£s into MILs. Because memory T cells in bone mε⧩arrow occur as a result of the immuneγ§☆ system’s recognition of tumor antigens, MILs₽"♠ are specifically suited for adoptive cellula±←♥λr immunotherapy and are able →Ω•to directly eradicate or facilitat₹λe eradication of each patient’s uniq÷→✔ue cancer. WindMIL is currently studyin♠ε→g MILs in multiple myeloma, non-small cell ÷≈lung cancer and squamous cell carcinoma o™∏≥f the head and neck,♣∞₹" and plans to expand into othe®‌r solid tumors.“WindMIL is looking forward to w$£orking with the University of ‌"λCalifornia, Irvine on thi¥Ωs exciting project and is optimistic tha•↕✔>t MILs may offer the potential to help patients"★ with these hard-to-treat diseases,” sai♥∏&d Monil Shah, PharmD, ≤₽₩MBA, Chief Development Officer at WindM≥≠γ®IL.information sou∑¥₩rce:pharma focus AsiaThe or♣‍∑ iginal link:https://www.pharmaf  "ocusasia.com/news/windmil-therapeutics-and-un↑&iversity-of-california-irvine-a‍♦ ↔nnounce-collaboration-to-collect-bone-marrow- π÷αfrom-patients-with-gliomas2019 Asia-pacific phar♠≈↔αma IP Leader Summit: http://en.zen↔&$seegroup.com/p/510934/will be hel <  d in Beijing  on €φNovember 14-15, and will attract more tha$§∑®n 500 industry experts from domestic and γδ≠foreign pharmaceutical₽γ​ companies, biotechnology companies, gov§↕ ernments, associations, law f≈σ™irms, intellectual pr→β→operty agents and other companies to attend✔ .Official registrati£©←on and consultation channels:Contact：AnnPho☆ ne: 021-65650305Email：Marketing@zenseegroup.£λ‍comhttp://en.zenseegroup.com/p/510934/